CXCL8 and ovarian cancer: Both moderate (52.48 mg) and high (106.26 mg) genistein supplementation significantly reduced the protein expression levels of IL-6, IL-8, VEGF, and TNF-α in the ovarian samples, indicating that genistein mediates its antiinflammation effects on ovarian cancer through an inflammation signaling pathway.